Lunai Bioworks(LNAI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LNAI Lunai Bioworks

Not Yet Opened 04-16 16:00:00 EDT

0.3040

-0.0189

-5.85%

盘后0.3060

+0.0020+0.66%

19:59 EDT

High0.3141	Low0.2777	Vol2.20M
Open0.3047	D1 Closing0.3229	Amplitude11.27%
Mkt Cap11.03M	Tradable Cap8.14M	Total Shares36.27M
T/O653.73K	T/O Rate8.20%	Tradable Shares26.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LNAI","market":"US","secType":"STK","nameCN":"Lunai Bioworks","latestPrice":0.304,"timestamp":1776369600000,"preClose":0.3229,"halted":0,"volume":2196424,"hourTrading":{"tag":"盘后","latestPrice":0.306,"preClose":0.304,"latestTime":"19:59 EDT","volume":217165,"amount":65360.4593,"timestamp":1776383953719,"change":0.002,"changeRate":0.006579,"amplitude":0.041447},"delay":0,"changeRate":-0.05853205326726549,"floatShares":26789600,"shares":36271119,"eps":-7.5469,"marketStatus":"Not Yet Opened","change":-0.0189,"latestTime":"04-16 16:00:00 EDT","open":0.3047,"high":0.3141,"low":0.2777,"amount":653734.45830768,"amplitude":0.112728,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-7.5469,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776412800000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":0.3229,"preHourTrading":{"tag":"盘前","latestPrice":0.2949,"preClose":0.3229,"latestTime":"09:28 EDT","volume":239408,"amount":69340.57217984,"timestamp":1776346080020,"change":-0.028,"changeRate":-0.086714,"amplitude":0.087024},"postHourTrading":{"tag":"盘后","latestPrice":0.306,"preClose":0.304,"latestTime":"19:59 EDT","volume":217165,"amount":65360.4593,"timestamp":1776383953719,"change":0.002,"changeRate":0.006579,"amplitude":0.041447},"volumeRatio":0.276488,"impliedVol":1.4337,"impliedVolPercentile":0.8209},"requestUrl":"/m/hq/s/LNAI/wiki","defaultTab":"wiki","newsList":[{"id":"2627128759","title":"Lunai Bioworks unit BioSymetrics signs LOI with Geneial on rare disease cohorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2627128759","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627128759?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:10","pubTimestamp":1776258650,"startTime":"0","endTime":"0","summary":"Lunai Bioworks unit BioSymetrics signed a non-binding letter of intent with Geneial to pursue a strategic collaboration in rare neurological disorders.Partnership targets creation of trial-ready patient cohorts by integrating patient-led datasets across multiple registries with longitudinal clinical data.Companies aim to use resulting cohorts to support commercial partnerships with pharmaceutical and biotechnology groups, creating potential revenue-generating collaborations.Initial focus covers select rare neurodevelopmental disorders, with plans to expand program scope over time.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL59NqSx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625037953","title":"Lunai Bioworks unit BioSymetrics wins first revenue-generating defense collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2625037953","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625037953?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:06","pubTimestamp":1775567177,"startTime":"0","endTime":"0","summary":"Lunai Bioworks unit BioSymetrics signed a revenue-generating, multi-year commercial defense collaboration with a specialized biotechnology partner to deploy an AI platform for chemical threat assessment.BioSymetrics will use zebrafish-based phenotypic screening with AI-driven mechanism-of-action prediction to identify and classify neuroactive or neurotoxic compounds.Lunai said additional defense-focused engagements are under discussion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire  on April 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL9g3Mty:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953783","title":"Lunai Bioworks (Nasdaq: Lnai) Secures First Revenue-Generating Defense Collaboration Through Biosymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953783","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953783?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:05","pubTimestamp":1775567100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA44DVK1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623324913","title":"Lunai Bioworks acquires Clemann Group BBB delivery platform in $20M deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2623324913","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623324913?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:41","pubTimestamp":1774906916,"startTime":"0","endTime":"0","summary":"Lunai Bioworks executed a binding $20 million transaction to acquire blood-brain barrier delivery technology and CNS Alzheimer’s drug assets from Clemann Group.Consideration uses Series B convertible preferred stock with a fixed $1.50 per-share conversion price.Conversion is subject to a 19.9% beneficial ownership cap.Assets include a delivery platform designed to cross blood-brain barrier, with activation intended to occur inside brain.Acquisition expands Lunai’s CNS pipeline beyond Alzheimer’s into other neurological disorders where brain penetration limits drug development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDLnYNhH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622478850","title":"Lunai Bioworks acquires Clemann Group BBB delivery technology and CNS Alzheimer’s assets; deal totals $20 million at $1.50 conversion price","url":"https://stock-news.laohu8.com/highlight/detail?id=2622478850","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622478850?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:51","pubTimestamp":1774529482,"startTime":"0","endTime":"0","summary":"Lunai Bioworks acquires Clemann Group BBB delivery technology and CNS Alzheimer’s assets; deal totals $20 million at $1.50 conversion price. Lunai Bioworks entered a binding strategic transaction valued at USD 20 million to acquire blood-brain barrier delivery technology and CNS Alzheimer’s drug assets from the Clemann Group.The consideration is structured as Series B convertible preferred stock with a fixed conversion price of USD 1.50 per share.The conversion is subject to a 19.9% beneficial ownership limitation.The acquired platform is intended to support delivery of therapeutics into the brain for Alzheimer’s and other CNS indications.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3fXRpj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622410850","title":"Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring Bbb Delivery Platform for CNS Alzheimer's Therapies With Broad CNS Delivery Applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2622410850","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622410850?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:51","pubTimestamp":1774529474,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E0L3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620133229","title":"Lunai Bioworks announces formation of Pathfinder Consortium","url":"https://stock-news.laohu8.com/highlight/detail?id=2620133229","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620133229?lang=en_us&edition=fundamental","pubTime":"2026-03-19 22:10","pubTimestamp":1773929431,"startTime":"0","endTime":"0","summary":"Lunai Bioworks (LNAI) announced the formation of a national consortium designed to accelerate the discovery and development of chemical countermeas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lunai-bioworks-announces-formation-of-pathfinder-consortium-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lunai-bioworks-announces-formation-of-pathfinder-consortium-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LNAI","BK4211","PBHC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620226176","title":"Lunai Bioworks launches Pathfinder Consortium to develop chemical countermeasures in 36 months","url":"https://stock-news.laohu8.com/highlight/detail?id=2620226176","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620226176?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:58","pubTimestamp":1773928715,"startTime":"0","endTime":"0","summary":"Lunai Bioworks said its BioSymetrics unit formed the Pathfinder Consortium to coordinate academic, military, and biotech efforts on chemical countermeasure discovery and development.The company described a development model aiming to complete efficacy and safety steps in about 36 months, including a 50-person Phase I safety study.The program includes screening in yeast and cell-based systems, followed by validation in FDA-recognized zebrafish models.Lunai said validated countermeasures are typically procured for U.S. government stockpiling programs ranging from USD 400 million to USD 1.2 billion per program.Named collaborators include Calum MacRae, Vik Bebarta, Randall Peterson, and Vincent Jo Davidson.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL3y24gL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619443143","title":"Tivic Subsidiary Velocity Bioworks Signs San Antonio Facility Leases","url":"https://stock-news.laohu8.com/highlight/detail?id=2619443143","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619443143?lang=en_us&edition=fundamental","pubTime":"2026-03-14 05:28","pubTimestamp":1773437298,"startTime":"0","endTime":"0","summary":"Tivic Health Systems Inc.’s wholly owned subsidiary Velocity Bioworks, Inc. entered into three facility agreements in San Antonio, Texas. Velocity Bioworks signed an eight-year lease for an 8,024-square-foot microbial facility with an option to extend and an option to purchase the property for $12.5 million within the first 24 months, a 102-month lease for a 20,144-square-foot mammalian facility, and a 110-month sublease for 8,122 square feet of office space that will serve as Tivic’s new principal executive office.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL5Dp1v8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI","TIVC","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617574329","title":"BRIEF-Lunai Bioworks Implements Temporary Furlough Of Employees In US And Canada- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617574329","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617574329?lang=en_us&edition=fundamental","pubTime":"2026-03-06 06:19","pubTimestamp":1772749169,"startTime":"0","endTime":"0","summary":"BRIEF-Lunai Bioworks Implements Temporary Furlough Of Employees In US And Canada- SEC FilingMarch 5  - SEC Filing:LUNAI BIOWORKS INC - IMPLEMENTS TEMPORARY FURLOUGH OF EMPLOYEES IN US AND CANADA ON FEB 27, 2026 - SEC FILINGLUNAI BIOWORKS INC - CEO AND CFO VOLUNTARILY AGREE TO TEMPORARILY DEFER SALARY PAYMENTS DURING FURLOUGH - SEC FILINGLUNAI BIOWORKS INC - AFFECTED EMPLOYEES WILL NOT PERFORM SERVICES OR RECEIVE COMPENSATION DURING FURLOUGH - SEC FILINGLUNAI BIOWORKS INC - MAINTAINS LIMITED OPERATIONS AND BEGINS RECALLING SOME OPERATIONAL EMPLOYEES FROM FURLOUGH - SEC FILINGSource text: [ID:n0001731122-26-000345]Further company coverage: LNAI.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nFWN3ZT0U2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617657904","title":"Lunai Bioworks Inc - Implements Temporary Furlough of Employees in US and Canada on Feb 27, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617657904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617657904?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:47","pubTimestamp":1772747277,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nFWN3ZT0U2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617571852","title":"Lunai Bioworks Inc - CEO and CFO Voluntarily Agree to Temporarily Defer Salary Payments During Furlough - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617571852","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617571852?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:47","pubTimestamp":1772747277,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nFWN3ZT0U2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617790955","title":"Lunai Bioworks Furloughs U.S. and Canada Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2617790955","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617790955?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:46","pubTimestamp":1772747207,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. has temporarily furloughed employees in the United States and Canada to preserve liquidity while it seeks additional financing. Furloughed workers will not provide services or receive pay during the period, and the length of the furlough depends on the company’s ability to raise capital. The CEO and CFO have also agreed to defer their salaries, and the company has begun recalling some operational staff to support ongoing development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 05, 2026, and is","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL7WHTKw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613260730","title":"Nasdaq Moves to Delist Lunai Bioworks Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2613260730","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613260730?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:33","pubTimestamp":1771882434,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. said it received a notice from Nasdaq’s Listing Qualifications Staff determining that the company’s securities should be delisted. The company has appealed and secured a Nasdaq Hearings Panel hearing scheduled for March 26, 2026, which stays the delisting pending a final decision, though the company cautioned there is no assurance it will be granted continued listing or regain compliance with Nasdaq requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 23, 2026, and is solely responsibl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDLbGHq3b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612400747","title":"Lunai Bioworks Secures U.S. Patent for AI Debiasing Framework in Drug Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2612400747","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612400747?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:32","pubTimestamp":1771507939,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. announced the issuance of U.S. Patent No. 12,369,861, titled “Methods, Systems, and Frameworks for Debiasing Data in Drug Discovery Predictions.” The patent covers multimodal data standardization and structural bias removal prior to predictive modeling, aimed at improving confidence in biomarker discovery, disease stratification, and gene network mapping.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDLFL072:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612953624","title":"Lunai Bioworks Inc. - Common Stock Q2 EPS $(0.08) Up From $(0.45) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2612953624","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612953624?lang=en_us&edition=fundamental","pubTime":"2026-02-18 06:03","pubTimestamp":1771365837,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. - Common Stock (NASDAQ:LNAI) reported quarterly losses of $(0.08) per share. This is a 82.22 percent increase over losses of $(0.45) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50674117/lunai-bioworks-inc-common-stock-q2-eps-0-08-up-from-0-45-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Lunai Bioworks Inc. - Common Stock Q2 EPS $(0.08) Up From $(0.45) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612946206","title":"Lunai Bioworks net income loss narrows to USD 1.80 million in Q4, down 75 percent","url":"https://stock-news.laohu8.com/highlight/detail?id=2612946206","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612946206?lang=en_us&edition=fundamental","pubTime":"2026-02-18 04:17","pubTimestamp":1771359446,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. reported its results for the quarter ending December 31, 2025. The company ended the period with cash and cash equivalents of USD 0.49 million and an accumulated deficit of USD 509.44 million, with a working capital deficit of USD 19.49 million. Management highlighted that there is substantial doubt about Lunai Bioworks’ ability to continue as a going concern due to recurring losses and reliance on additional financing. During the period, Lunai Bioworks completed the acquisition of BioSymetrics Inc. and its subsidiary on April 8, 2025. Earlier, GediCube, B.V., previously acquired in 2024, filed for bankruptcy and ceased operations. Additionally, the company changed its corporate name from Renovaro Inc. to Lunai Bioworks Inc. on August 20, 2025. Management stated that future funding is expected to support ongoing obligations, product commercialization, clinical and regulatory development, and working capital needs.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL22QZyt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611774157","title":"Lunai Bioworks CEO Showcases AI Drug Discovery Platform on CNBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2611774157","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611774157?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:32","pubTimestamp":1770989548,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire  on February 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL5bLrLq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611597025","title":"Nasdaq Moves to Delist Lunai Bioworks for Minimum Bid Price Violation","url":"https://stock-news.laohu8.com/highlight/detail?id=2611597025","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611597025?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:17","pubTimestamp":1770931075,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. is facing potential delisting from the Nasdaq Capital Market after receiving notice from Nasdaq that the company is not in compliance with the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5550. The company's stock traded below this threshold for 30 consecutive business days, triggering the notice. Due to a 1-for-10 reverse stock split conducted within the past year, Lunai Bioworks is not eligible for a standard 180-day compliance period. The company has requested a hearing to appeal the delisting determination, which temporarily stays the suspension of its securities pending the outcome. If the appeal is unsuccessful or not filed by the deadline, Lunai Bioworks’ shares will be suspended from trading and officially delisted.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL15cqnQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610629968","title":"Lunai Bioworks Unveils AI Platform Targeting Disease Subtypes for Precision Drug Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2610629968","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610629968?lang=en_us&edition=fundamental","pubTime":"2026-02-10 22:52","pubTimestamp":1770735173,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. has released a presentation detailing its approach to drug discovery and development. The company highlights its proprietary Augusta platform, which utilizes artificial intelligence to analyze clinical-grade patient data and identify biologically distinct subtypes within complex diseases. This process enables the design and early validation of precision-matched therapies in living systems, aiming to reduce clinical failure risk, accelerate development timelines, and improve capital efficiency. The presentation also addresses industry challenges such as rising development costs, lengthy timelines, and the impact of patent expirations on pharmaceutical revenues. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLP7V05:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.renovarogroup.com","stockEarnings":[{"period":"1week","weight":-0.0955},{"period":"1month","weight":0.5238},{"period":"3month","weight":-0.6487},{"period":"6month","weight":-0.7309},{"period":"1year","weight":-0.9136},{"period":"ytd","weight":-0.6338}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.014032},{"month":2,"riseRate":0.375,"avgChangeRate":-0.059392},{"month":3,"riseRate":0.375,"avgChangeRate":-0.055345},{"month":4,"riseRate":0.25,"avgChangeRate":-0.098792},{"month":5,"riseRate":0.5,"avgChangeRate":-0.0442},{"month":6,"riseRate":0.375,"avgChangeRate":-0.147122},{"month":7,"riseRate":0.625,"avgChangeRate":-0.018947},{"month":8,"riseRate":0.625,"avgChangeRate":0.533577},{"month":9,"riseRate":0.375,"avgChangeRate":-0.022213},{"month":10,"riseRate":0.5,"avgChangeRate":-0.035033},{"month":11,"riseRate":0.75,"avgChangeRate":0.142505},{"month":12,"riseRate":0.375,"avgChangeRate":-0.12056}],"exchange":"NASDAQ","name":"Lunai Bioworks","nameEN":"Lunai Bioworks"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lunai Bioworks(LNAI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Lunai Bioworks(LNAI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Lunai Bioworks,LNAI,Lunai Bioworks股票,Lunai Bioworks股票老虎,Lunai Bioworks股票老虎国际,Lunai Bioworks行情,Lunai Bioworks股票行情,Lunai Bioworks股价,Lunai Bioworks股市,Lunai Bioworks股票价格,Lunai Bioworks股票交易,Lunai Bioworks股票购买,Lunai Bioworks股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lunai Bioworks(LNAI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Lunai Bioworks(LNAI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}